Allergic Contact Dermatitis (ACD) is a common inflammatory skin condition resulting from an immune-mediated reaction to an allergen that encounters the skin. During initial exposure, the immune system becomes sensitized to the allergen, and upon subsequent exposures, a localized allergic response characteristic of ACD develops. The molecular events underlying the skin sensitization adverse outcome pathway (AOP) are well characterized. This has enabled the development of validated in chemico and in vitro assays to assess the sensitization potential of chemical substances.
 

At Cyprotex, we offer the suite of assays in accordance with the OECD test guideline 442 series, designed to identify skin sensitizers by targeting key events in the AOP, including the molecular initiating event (protein binding), keratinocyte activation, and dendritic cell (immune) activation.